Overview
Quick answer
If a report came back with high cholesterol, the first job is to read the stationery, not a US webpage. Australian labs print lipids in mmol/L. A flagged total cholesterol is usually 5.5 mmol/L or above. That flag is a prompt to look at absolute cardiovascular risk. It is not a diagnosis, and it does not mean you have plaque.
Almost one in three Australian adults (30.2%) had total cholesterol of 5.5 mmol/L or above in 2022 to 2024 (ABS National Health Measures Survey). Only 9.2% of that group said they already knew they had high cholesterol as a long-term condition. The number is common. The useful next question is what the rest of the panel, and the rest of your risk, actually show.
The 2023 Australian guideline, led by the Heart Foundation and endorsed by the RACGP, starts lipid-modifying treatment from five-year absolute CVD risk, not from an LDL cholesterol target. High risk is 10% or above on the Aus CVD Risk Calculator. The calculator uses the total-cholesterol-to-HDL ratio. LDL-C is not an input. ApoB and Lp(a) are extra lines, usually private, for when the standard panel and the story disagree.
Overview
Key takeaways
Australian lipid reports use mmol/L. A US page quoting LDL of 100 is a different scale. Do not mix the two.
A standard GP panel is total cholesterol, triglycerides, and HDL-C, with LDL-C and non-HDL-C usually calculated. ApoB and Lp(a) are not on that opening set.
The H or L flag is an AACB decision limit (total cholesterol 5.5 mmol/L, LDL-C 3.0 mmol/L), not a treatment order and not a plaque finding.
Australian primary prevention in 2023 treats from five-year absolute risk of 10% or above, and considers treatment between 5% and 10%. It does not set a primary-prevention LDL target.
The calculator lipid input is the total-cholesterol-to-HDL ratio. That is why a "normal LDL" can still sit inside a high-risk score, and a flagged LDL can sit inside a low one.
LDL-C measures cholesterol cargo. ApoB counts atherogenic particles. When the two disagree, risk tracks the particle number. That is the reason to add ApoB, not a claim that ApoB is always better.
Lp(a) is mostly genetic and is measured once. It can explain early family heart disease when the standard panel looks ordinary.
Blood cannot image an artery. Coronary calcium scoring is a CT, used only when the treatment decision is uncertain, not a second cholesterol test.
The frame
Why a high cholesterol result is not a diagnosis
High cholesterol is a lab description, not a disease name. The same phrase covers a slightly flagged total cholesterol in an otherwise well 48-year-old, a calculated LDL that is invalid because triglycerides are high, familial hypercholesterolaemia, and a person already on a statin whose residual risk lives in ApoB or Lp(a).
That is why a good next step is to read the printout against Australian rules, then decide whether the standard panel is enough. The page people join from is not "how to lower cholesterol." It is what the blood can show, what it cannot, and which extra test is actually doing a job.
Common on the report, often unnoticed
ABS 2022 to 2024 found 30.2% of adults at or above 5.5 mmol/L total cholesterol, and 27.8% with fasting LDL-C at or above 3.5 mmol/L. Among people who met the survey definition of dyslipidaemia, 69.6% were not on lipid-lowering medicine. A flagged line is ordinary Australian pathology, not a rare event.
The flag is a review prompt, not a verdict
The Australasian Association of Clinical Biochemists 2018 harmonisation guideline says the printed limits are neither population reference intervals nor clinical action limits. A flag means review absolute cardiovascular risk. It does not, by itself, start a medicine.
One number cannot carry the decision
The 2023 calculator also needs age, sex, smoking, systolic blood pressure, diabetes, postcode, atrial fibrillation, and current CVD medicines. Cholesterol is one input. Treating the lipid line in isolation is the habit the current guideline was written to stop.
If you came here hoping the report would tell you whether your arteries are blocked, this is the honest frame: blood measures circulating lipoproteins. Imaging measures arteries. Risk calculators combine both kinds of information with things blood never sees.
The panel
What a standard lipid panel measures
The RCPA Manual (Lipids, last reviewed 2 January 2024) describes a lipid profile as total cholesterol, triglyceride, and HDL cholesterol, with calculation of non-HDL cholesterol and estimation of LDL cholesterol. That is the standard Australian GP panel. ApoB and Lp(a) are separate assays.
Total cholesterol
Every cholesterol-carrying particle in the sample, added together. Easy to flag, easy to over-read. It does not say how many particles there are, or which ones.
HDL cholesterol
Cholesterol inside high-density lipoprotein particles. Used in the 2023 calculator as the denominator of the TC:HDL ratio. "Good cholesterol" is a slogan, not a mechanism. HDL-C is a marker, not a treatment target you raise in isolation.
Triglycerides
Fat the liver packages into VLDL. High triglycerides make LDL-C harder to interpret and are one of the settings where ApoB earns its keep. Fasting is optional for a first panel; a repeat to confirm a high triglyceride is often done fasting.
LDL-C, usually calculated
In mmol/L the Friedewald estimate is total cholesterol minus HDL-C minus (triglycerides divided by 2.2). It is not a direct count of LDL particles. The estimate is invalid when triglycerides are above 4.5 mmol/L; the lab then needs a direct LDL assay or should lean on non-HDL-C and ApoB.
Non-HDL cholesterol
Total cholesterol minus HDL-C. It captures the cholesterol in every atherogenic particle, including VLDL remnants, without needing a Friedewald assumption. It is still cholesterol mass, not particle number. RCPA notes accumulating evidence that non-HDL-C and ApoB outperform LDL-C for risk prediction. That is lab commentary, not a change in the 2023 treatment rule.
ApoB and Lp(a) are add-ons
Neither is part of the standard GP panel. Both are classified by the RCPA Manual as non-MBS-rebatable immunoassays. They are the useful next tests when the standard panel and the clinical story disagree, not extras to order by default on every flagged cholesterol.
A non-fasting sample is now regarded as a suitable alternative for a routine lipid profile (RCPA Manual; AACB 2018). Fasting status should still be recorded. Pathology Tests Explained (updated 26 February 2025) notes that many laboratories prefer non-fasting, and that an 8 to 12 hour fast may be asked for a repeat to confirm an abnormal result. Australian Prescriber 2024 still prefers fasting where possible when triglycerides are high or you are comparing two results over time.
Reading your results
How to read an Australian lipid printout
Australian pathology reports print each marker with the lab's own name, unit, and interval. Field names vary. Match the row, not a remembered US unit.
"Cholesterol" or "Total cholesterol"
In mmol/L. AACB 2018 and Pathology Tests Explained flag above 5.5 mmol/L. That is the same cut-off ABS uses for "abnormally high" in the 2022 to 2024 survey. The flag is a decision limit, not a population plus-or-minus-two-standard-deviations interval.
"LDL" or "LDL cholesterol"
In mmol/L, usually calculated. AACB flags above 3.0 mmol/L. RCPA still prints older risk-stratified aims (under 3.0, 2.5, or 1.8 depending on risk). Those aims sit beside the 2023 guideline, which does not set a primary-prevention LDL target. A flag here is not an order to treat.
"HDL" or "HDL cholesterol"
In mmol/L. AACB and RCPA flag below 1.0 in men and below 1.2 in women. ABS used a stricter female cut-off of 1.3 mmol/L in 2022 to 2024. If a webpage and your report disagree about a female HDL, check which definition they used.
"Triglycerides" or "Triglyceride"
In mmol/L. AACB and RCPA flag above 2.0 mmol/L (fasting). Very high triglycerides (above 4.5) break the Friedewald LDL estimate. The row may then be blank, asterisked, or replaced by a direct LDL.
"Non-HDL" or "Non HDL cholesterol"
In mmol/L. Calculated as total cholesterol minus HDL-C. RCPA gives risk-stratified aims of under 3.8, 3.3, or 2.6 mmol/L depending on risk, not a single flat cut-off. Useful when LDL-C is missing or untrustworthy.
"Chol/HDL" or "TC/HDL ratio"
This ratio is the lipid input to the 2023 Aus CVD Risk Calculator. LDL-C is not. If your report prints the ratio, that is the number the guideline actually uses. If it does not, the calculator can still derive it from total cholesterol and HDL-C.
Cholesterol can differ by as much as 10% from one month to the next (Pathology Tests Explained). Levels also fall for up to eight weeks after a heart attack or acute infection, and a prolonged tourniquet can raise them by up to 20% (RCPA Cholesterol). Confirm a surprising result before you build a story on it.
Mechanism
Why LDL-C can mislead
LDL-C is the number most people are shown, and it is a weaker story than it looks. The weakness is mechanistic, not a slogan.
Cargo versus particle count
LDL-C measures millimoles of cholesterol inside LDL particles. Particle size and cholesterol content vary. Small, cholesterol-depleted LDL can leave LDL-C looking ordinary while many particles are still circulating (Sniderman et al., JAMA Cardiology, 2019).
One ApoB per atherogenic particle
Each VLDL, IDL, LDL, and Lp(a) particle carries one ApoB molecule. Plasma ApoB therefore estimates how many particles can enter an artery wall. ESC/EAS 2019: because those particles contain a single ApoB, quantitation of ApoB directly estimates atherogenic particle number.
Discordance is the test
When LDL-C, non-HDL-C, and ApoB agree, they rank risk similarly. ESC/EAS 2019 notes they are very highly correlated under most circumstances. In around 20% of patients they disagree. When they disagree, risk tracks the particle number. Discordance is more common with high triglycerides, diabetes, obesity, or a very low on-treatment LDL-C.
That is not "ApoB is always better"
Concordance is the usual case. The 2023 Australian guideline says non-HDL-C and ApoB are better predictors than LDL-C, and still does not put them in the calculator. The honest use of ApoB is to resolve a mismatch, not to replace every standard panel.
If your LDL-C is flagged and your triglycerides, HDL-C, and calculated risk all point the same way, you may not need a second assay to understand the story. If the panel is mixed, or you already sit on treatment with residual risk, particle number is the next question.
Next test
ApoB and particle number
ApoB is the particle-count test. This hub only needs the reason to order it. The marker guide covers ranges, costs, and how to get it.
What it adds
ApoB answers "how many atherogenic particles?" when LDL-C cannot. That is most useful when triglycerides are high, when you have diabetes or metabolic syndrome, or when LDL-C looks fine and family history or calculated risk does not.
How Australian labs print it
The RCPA Manual (Apolipoprotein B, last reviewed 6 February 2024) reports ApoB in g/L, with interpretation bands of under 1.00 g/L for high cardiovascular risk and under 0.80 g/L for very high risk. That is not the same scale as mmol/L on the lipid panel, and it is not a US mg/dL printout.
Medicare does not list a routine item
RCPA classifies the immunoassay as non-MBS-rebatable. MSAC application 1512, which asked for ApoB in high-risk CVD assessment, was not supported. A GP can still request it as a private add-on. Typical standalone prices already published on Hemexa's ApoB guide are about $30 to $80, not re-priced this session.
The 2023 guideline says routinely measuring ApoB in people without known CVD is not currently recommended for the risk-estimating algorithm. That is a calculator decision, not a claim that the assay is useless.
For ranges, private costs, and how to order the assay, see the ApoB test guide.
Next test
Lipoprotein(a)
Lp(a) is a genetically set particle. Diet and most medicines barely move it. One measurement in adult life is the usual plan.
What it adds
Lp(a) can explain early heart disease or aortic valve disease in a family when the standard lipid panel looks ordinary. It is independent of LDL-C. You can have low LDL-C and high Lp(a), or the reverse.
How Australian labs should print it
The Australian Atherosclerosis Society 2023 position statement says results should be reported in molar units (nmol/L). The RCPA Manual (last reviewed 30 September 2024) gives a reference interval of under 75 nmol/L. Some reports may still show mg/dL. Do not mix the two.
Also non-MBS-rebatable
RCPA classifies the immunoassay as non-MBS-rebatable. MSAC application 1736 was still pending when this page was written. Typical standalone prices already published on Hemexa's Lp(a) guide are about $40 to $90. The 2023 CVD guideline sees no justification for population screening, and supports selective use in secondary prevention, familial hypercholesterolaemia, premature or recurrent events, or suboptimal LDL-C lowering.
A high Lp(a) raises lifetime risk. It does not say when an event will happen. The current clinical response is to treat the risk you can change, not to wait for an Lp(a)-specific drug.
For nmol/L vs mg/dL, one-time testing, and how to order, see the Lipoprotein(a) test guide.
Australian practice
Absolute risk, not an LDL target
This is the section most Australian consumer pages still get wrong. They either import a US LDL target or keep quoting the 2012 Framingham 15% band.
Still a five-year calculator
The 2023 Australian Guideline for assessing and managing cardiovascular disease risk replaced the 2012 NVDPA guideline. The Aus CVD Risk Calculator estimates five-year risk, not ten-year risk. High is 10% or above. Intermediate is 5% to under 10%. Low is under 5%. The new 10% band is described as likely comparable to the old 15% Framingham band, not identical to it.
Treat risk, not an LDL number
For high risk, the guideline says prescribe lipid-modifying medicines unless they are contraindicated or clinically inappropriate. For intermediate risk, consider them. Australian Prescriber 2024 notes the guideline does not explicitly mention treatment targets for elevated LDL-C. European and American guidelines still assign LDL targets by risk. That is their policy, not Australia's primary-prevention rule.
The lipid input is the TC:HDL ratio
Inputs include age, sex, smoking, systolic blood pressure, the total-cholesterol-to-HDL ratio, diabetes, CVD medicines, postcode, and atrial fibrillation. LDL-C is not an input. A person can have a flagged LDL and a low calculated risk, or a quiet LDL and a high one.
A few lipids still override the score
Very high cholesterol, meaning total cholesterol above 7.5 mmol/L, warrants lipid-modifying treatment regardless of calculated risk. A confirmed diagnosis of familial hypercholesterolaemia is assessed as high risk by default, bypassing the calculator entirely. LDL-C above 5 mmol/L is not itself a treat-regardless threshold; Australian Prescriber 2024 flags it as a prompt to consider a genetic cause such as FH, not a calculator bypass in its own right.
Who to assess, if there is no known CVD: ages 45 to 79; 35 to 79 with diabetes; 30 to 79 for Aboriginal and Torres Strait Islander people, with risk-factor review from 18. Reassess untreated intermediate risk at about two years, and low risk at about five. Once you are on treatment, the guideline generally does not ask for formal recalculation just to watch the LDL flag.
Lowering LDL-C still reduces events. The Cholesterol Treatment Trialists' Collaboration (Lancet, 2010) found a 22% proportional reduction in major vascular events per 1.0 mmol/L LDL-C reduction across 26 trials. The Australian choice is when to start a medicine, not whether LDL-C biology is real.
A special case
Familial hypercholesterolaemia
Most high cholesterol is not familial hypercholesterolaemia. A subset is, and it is easy to miss if you only stare at a 5.5 flag.
An estimate, not a census
CSANZ-published Australian guidance (Watts et al., Heart, Lung and Circulation, 2021) says recent epidemiological studies indicate the overall prevalence of FH in the general population may be as high as 1 in 250, implying about 100,000 Australians, including children. That is an international-epidemiology estimate applied to Australia, not an ABS blood-survey count.
Most are undiagnosed
AJGP 2021, citing that guidance, says it affects one in 250 to 300 Australians and that fewer than 10% of those estimated 100,000 people are diagnosed. A very high isolated cholesterol, especially with tendon xanthomas or early family coronary disease, is a reason to use FH-specific guidance rather than the ordinary calculator.
Gene testing is a specialist item
MBS item 73352 funds germline testing of LDLR, PCSK9, and APOB when a specialist requests it and clinical criteria are met. It is not a GP screening blood test, and it is not the same assay as serum ApoB.
If total cholesterol is above 7.5 mmol/L, or close relatives had heart attacks young, ask your GP about FH pathways. Do not treat a webpage estimate as your diagnosis.
Limits
What blood tests cannot show
A lipid panel reports circulating lipoprotein cholesterol, triglycerides, and, if you add them, ApoB or Lp(a). It does not photograph an artery.
Plaque and atherosclerosis
High cholesterol raises the probability that atherogenic particles will enter an artery wall over decades. The report does not show whether that has already happened. A flagged LDL is not a blocked artery.
Coronary calcium and CT coronary angiograms
A calcium score (CAC) and a CT coronary angiogram are imaging. The 2023 guideline does not recommend CAC for generalised population screening. It may reclassify risk when the treatment decision is uncertain. It is not a second cholesterol test, and it is not indicated if you already have known coronary disease or are already high risk.
Blood pressure, smoking, and postcode
The calculator needs systolic blood pressure, smoking status, and socioeconomic disadvantage by postcode. None of those appear on a lipid printout. A perfect lipid panel does not cancel them.
When an event will happen
Even a high Lp(a) or a high five-year score is a probability, not a date. Blood cannot tell you that.
Chest pain, sudden shortness of breath, or symptoms that sound like a heart attack or stroke are not a lipid-panel question. Those belong in emergency care, not on a preventative membership page.
How to order
How Australians get these tests
| Approach | Best for | Typical cost | What it covers |
|---|---|---|---|
| GP-ordered Medicare lipid panel | A Heart Health Check, a first flagged result, or calculated CVD risk | Often bulk-billed or low gap when clinically indicated. MBS 66500 (cholesterol and triglycerides) and 66536 (HDL-C) are the funded assays. | Total cholesterol, triglycerides, HDL-C, with calculated LDL-C and non-HDL-C. Not ApoB. Not Lp(a). |
| GP-ordered private add-on | Discordant lipids, residual risk on treatment, or a family history the standard panel does not explain | ApoB about $30 to $80 and Lp(a) about $40 to $90 as already published on the marker guides, not re-priced this session | ApoB, Lp(a), or both, on the same form as the standard panel |
| Private comprehensive panels | A one-off preventative heart panel that already includes advanced lipids | Often $80 to $300+ depending on what else is on the form | Whatever is written on the request. You still need an authorised GP request. |
| Membership platforms (e.g. Hemexa) | Standard lipids twice a year, ApoB each baseline, and Lp(a) once, then a trend | ~$1,199/year (full membership) | Total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C, the TC:HDL ratio, ApoB, and Lp(a) among 76–80 signature markers |
Pathology in Australia requires an authorised request from a registered medical practitioner. Collection for Hemexa members is through Healius Pathology, with regional brands that differ by state. A request form is not a diagnosis, and a membership is not a substitute for a GP visit about chest pain or a very high isolated cholesterol.
FAQ
Frequently asked questions
- What does high cholesterol mean on an Australian report?
- It usually means total cholesterol is at or above 5.5 mmol/L, the AACB decision limit and the ABS "abnormally high" cut-off. The flag is a prompt to look at the rest of the panel and at five-year absolute CVD risk. It is not a diagnosis of heart disease, and it does not mean you have plaque.
- If my LDL is flagged, do I need a statin?
- Not from the flag alone. The 2023 Australian guideline starts lipid-modifying treatment from five-year risk of 10% or above, and considers it between 5% and 10%. Total cholesterol above 7.5 mmol/L is treated regardless of the score. Your GP puts the lipid line next to blood pressure, smoking, diabetes, age, and postcode. This page cannot make that call.
- Do I need to fast for a cholesterol blood test?
- Not routinely. RCPA and AACB 2018 treat a non-fasting sample as suitable for a standard lipid profile, and fasting status should be recorded. A repeat to confirm high triglycerides is often done after an 8 to 12 hour fast, water only. If the same form includes fasting glucose or insulin, you fast for the visit.
- Is ApoB better than LDL cholesterol?
- They measure different things. LDL-C is cholesterol cargo. ApoB is particle number. They usually agree. When they do not, risk tracks ApoB. That is why the assay exists. It is not a reason to call ApoB always better, and the 2023 Australian calculator still does not use it.
- How much do high cholesterol blood tests cost in Australia?
- A standard GP lipid panel is often bulk-billed or low gap when clinically indicated. MBS item 66500 covers cholesterol and triglycerides (schedule fee $9.70) and item 66536 covers HDL-C (schedule fee $11.05). Calculated LDL-C and non-HDL-C have no extra item. ApoB and Lp(a) are non-MBS-rebatable; typical private add-on prices already published on Hemexa's marker guides are about $30 to $80 for ApoB and $40 to $90 for Lp(a). Memberships that include these markers on a panel of 76–80 signature markers start around AU$1,199 per year.
- What is familial hypercholesterolaemia?
- An inherited condition that keeps LDL-C very high from a young age. Australian CSANZ-published guidance estimates it may affect as many as 1 in 250 people, about 100,000 Australians, and that most are undiagnosed. That is an epidemiological estimate, not a national blood-survey count. Total cholesterol above 7.5 mmol/L, or early heart disease in close relatives, is a reason to ask about FH-specific care, not to self-diagnose from a webpage.
- Can a blood test show plaque in my arteries?
- No. Blood measures circulating lipoproteins. Plaque is an imaging finding. A coronary calcium score is a CT, not a cholesterol test, and the 2023 guideline does not recommend it for generalised screening.
- Does Hemexa test cholesterol, ApoB, and Lp(a)?
- Yes. The annual baseline includes total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C, the TC:HDL ratio, ApoB, and Lp(a), among 76–80 signature markers. The standard lipids repeat on the included six-month retest. ApoB is annual. Lp(a) is measured once, on your first baseline. Collection is through Healius Pathology. A membership does not replace a GP visit for chest pain or a very high isolated result.
How Hemexa fits
How Hemexa can help
A flagged cholesterol line is common. The useful product move is to put the standard panel, ApoB, and a once-only Lp(a) on one record, then read them against each other instead of as a stack of PDFs.
Standard lipids twice a year
Hemexa includes total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C, and the TC:HDL ratio on the annual baseline and again on the included six-month retest, part of 76–80 signature markers. Those markers are biannual because they move with diet, weight, and treatment.
ApoB each baseline, Lp(a) once
ApoB runs on the annual baseline, not on the six-month retest. Lp(a) is measured once, on your first baseline, then carried forward as a lifetime reference. That matches how the markers behave: ApoB is modifiable, Lp(a) is mostly not.
Dashboard bands are Hemexa policy
The member app applies Hemexa preventative bands to these markers. Those bands are company clinical policy, not the 2023 Heart Foundation treatment rule, and not a claim that Australian GPs have moved to ApoB as the target.
Collection through Healius Pathology
Healius Pathology is Hemexa's collection partner, with regional brands that differ by state. Results from other Australian labs can be imported after your first baseline. The partner is the network, not one state brand.
Sources
References
Australian Bureau of Statistics. National Health Measures Survey, 2022-24. View source ↗
Australian Bureau of Statistics. Cardiovascular disease (CVD) biomarkers, Intergenerational Health and Mental Health Study: Concepts, Sources and Methods, 2020-24. View source ↗
Commonwealth of Australia, Department of Health and Aged Care. Australian Guideline for assessing and managing cardiovascular disease risk. 2023. View source ↗
Nelson, M. R., et al. (2024). 2023 Australian guideline for assessing and managing cardiovascular disease risk. Medical Journal of Australia, 220(9). View source ↗
Nelson, A. J. (2024). Managing hypercholesterolaemia. Australian Prescriber, 47, 9-14. View source ↗